PLX
Protalix BioTherapeutics, Inc.1.8100
+0.0700+4.02%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
145.56MP/E (TTM)
22.63Basic EPS (TTM)
0.08Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
8-K
CHMP rejects Elfabrio's E4W dosing
Protalix BioTherapeutics and partner Chiesi Global Rare Diseases announced on October 17, 2025, that the EMA's CHMP issued a negative opinion on approving Elfabrio's every-four-week 2 mg/kg dosing regimen in the EU, while the every-two-week 1 mg/kg option remains approved. This setback, based on data from the BRIGHT trial and extensions showing nearly six years of exposure, disappoints efforts to reduce treatment burden for Fabry patients. Yet the companies stay committed to advancing solutions. The every-two-week regimen endures.
8-K
ATM agreement amended
Protalix BioTherapeutics amended its at-the-market offering agreement with H.C. Wainwright & Co. on August 22, 2025, to align with a new Form S-3 registration statement effective that date. This update enables ongoing sales of common stock shares without fixed pricing. The move bolsters funding flexibility amid biotech volatility. No specific offering amounts disclosed.
LXRX
Lexicon Pharmaceuticals, Inc.
1.20-0.03
PKTX
ProtoKinetix, Inc.
0.00+0.00
PLRX
Pliant Therapeutics, Inc.
1.25+0.01
PLUR
Pluri Inc.
2.96-0.06
PROK
ProKidney Corp.
2.20+0.12
PRQR
ProQR Therapeutics N.V.
2.27-0.18
PSTV
PLUS THERAPEUTICS, Inc.
0.64+0.01
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
TARA
Protara Therapeutics, Inc.
5.42-0.08
TLX
Telix Pharmaceuticals Limited
8.34-0.29